Preventing and treating vitamin A deficiency is the first step in preventing systemic and ocular complications, including xerophthalmia, according to Alfred Sommer, MD, MHS.
Eculizumab (Soliris, Alexion) has been cleared by the U.S. Food and Drug Administration to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with a specific biomarker.
In this video, Robert Maloney, MD, discusses the efficacy of the iDESIGN system (Johnson & Johnson Vision,) and the positive outcomes patients have experienced.
OIS is facilitating meaningful interactions and the exchange of information between industry and clinical leaders since 2009. Save on attendance by taking advantage of the discounted Double Play package: https://ois.net/register/
Elevate the premium cataract experience in your practice with InSight Magazine, a resource to help patients understand their options for a full range of vision. Download the magazine today.
ADVERTISEMENT
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
